Congratulations to WeRide Inc.（0800.HK） on its successful Listing on the Mainboard of HKSE on 6 Nov 2025
WeRide Inc.is one of the global pioneers in L4 autonomous driving. Its robotaxi services are among the first in the world to achieve scaled commercial operation in both China and the Middle East.
With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services on financial instruments and intellectual property.
Congratulations again WeRide Inc.（0800.HK） on its successful listing. The issue price of the shares is  HKD 27.1 per share, and the amount of funds raised is HKD 2,391.58 million.
<img src="../../../../../uploads/1_f7bcec340d.JPG" alt="" width="960" height="720" />

banner1

Congratulations to WeRide Inc.（0800.HK）on its Successful Listing

Congratulations to Vigonvita Life Sciences Co., Ltd. （2630.HK） on its successful Listing on the Mainboard of HKSE on 6 Nov 2025
Vigonvita Life Sciences Co., Ltd. （the “Vigonvita”） is a biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of small-molecule drugs in its strategically focused therapeutic areas, namely neuropsychiatry and reproductive health.
With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services related to share-based compensation and intangible asset impairment test.
Congratulations again Vigonvita Life Sciences Co., Ltd. （2630.HK） on its successful listing. The issue price of the shares is  HKD 33.37 per share, and the amount of funds raised is HKD 587 million.
<img src="../../../../../uploads/1_9b1b7834fd.JPG" alt="" width="960" height="720" />

Congratulations to Vigonvita Life Sciences Co., Ltd. （2630.HK） on its Successful Listing

We are pleased to announce that our Managing Partner, Mr. Vincent Pang and our Director of Risk Management Advisory Services, Ms. Sabrina Lam have once again been invited by the Hong Kong Institute of Certified Public Accountants (HKICPA), for the seventh consecutive year, to serve on the Review Panel for the Best Corporate Governance (CG) and ESG Awards 2025.  AVISTA is honored to sponsor these prestigious awards. The Awards Presentation Luncheon took place successfully at the JW Marriott Hotel Hong Kong on 31st October 2025.
<img src="../../../../../uploads/Photo_1_10a22bf365.jpg" alt="" width="533" height="355" />
These awards highlight the critical importance of robust corporate governance and effective environmental, social, and governance (ESG) practices for listed companies and public sector/not-for-profit organizations, along with their investors and stakeholders. They serve as a catalyst for companies and organizations to strive for excellence in CG and ESG, encouraging them to weave these principles into their core values, strategies, and operations.
This year, 39 outstanding awardees were recognized, featuring leading companies in Hong Kong or even around the globe, including CLP Holdings Limited, MTR Corporation Limited, The Airport Authority Hong Kong, Swire Properties Limited, Hang Lung Group Limited, Tencent Holdings Limited, AIA Group Limited, ANTA Sports Products Limited, among others.
<img src="../../../../../uploads/Image_b43f290bab.jfif" alt="" width="533" height="404" />
As a leading provider of CG and ESG advisory services, AVISTA is excited to see substantial advancements in corporate CG and ESG reporting standards. We anticipate further improvements from companies in the years ahead. Our dedication to sustainability is unwavering, and we will keep supporting this critical field.

As a Reviewer and a Sponsor of the Best Corporate Governance (CG) and ESG Awards 2025 Organized by Hong Kong Institute of Certified Public Accountants (HKICPA)

Deepexi Technology Co., Ltd. （the “Deepexi”） is an enterprise large model AI application solution provider. With over 40 registered patents, Deepexi has participated in drafting several national standards in AI and industrial fields. Deepexi specializes in delivering cutting-edge artificial intelligence solutions for enterprises, empowering enterprises to integrate their professional knowledge and data, decisions and operations efficiently at scale.
With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services on share reform, and valuation services related to share-based compensation and preferred shares.
Congratulations again Deepexi Technology Co., Ltd. （1384.HK） on its successful listing. The issue price of the shares is  HKD26.66 per share, and the amount of funds raised is HKD710.01 million.
<img src="../../../../../uploads/1_908bce0acc.JPG" alt="" width="960" height="720" />

Congratulations to Deepexi Technology Co., Ltd. （1384.HK） on its successful Listing on the Mainboard of HKSE on 28 Oct 2025

Our Managing Partner, Mr. Vincent Pang, and Director, Ms. Sabrina Lam, had the honor of being invited as speakers by the Hong Kong Institute of Certified Public Accountants (HKICPA) to participate in 2nd Cohort of the GBA CPA Talent Class respectively.
Mr. Pang delivered an insightful presentation focusing on the requirements and issues of valuation in relation to M&amp;A transactions, accompanied by tasks upon completion of the transaction such as purchase price allocation and subsequent impairment assessment for the goodwill and intangible assets recognized in the transaction.
Ms. Lam’s presentation focused on the HKEX climate-related disclosure enhancement, including ESG reporting. Ms. Lam also shared valid examples to ensure her insights with fellow professionals were inspirational and enriching, such as navigating the key challenges for listed companies.
Drawing upon our deep expertise in business valuation and extensive industry experience, AVISTA Group is grateful for the opportunity to contribute to the advancement of the accounting profession through collaborations with the HKICPA. We eagerly anticipate future partnerships and opportunities to further enhance industry knowledge and practices.
 
<img src="../../../../../uploads/Image_6_08bdd86cde.jpg" alt="" width="800" height="600" />
<img src="../../../../../uploads/1_c0e451603f.jpg" alt="" width="800" height="600" />

As a speaker of the HKICPA’s 2nd Cohort of the GBA CPA Talent Class - Driving Excellence in Valuation and Sustainability

Congratulations to JST Group Corporation Limited (6687.HK) on its successful Listing on the Mainboard of HKSE on 21 Oct 2025
JST Group Corporation Limited (the “JST”) is a leading e-commerce SaaS ERP provider in China. JST’s offerings provide customers of different kinds and sizes a unified and intuitive way to monitor, operate and manage their businesses, and make data-driven intelligent decisions that help them excel in the fast-evolving e-commerce industry.
With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation services on PPA, goodwill impairment test, long-term asset impairment test, share-based compensation, financial instruments and financial assets.
Congratulations again JST Group Corporation Limited (6687.HK) on its successful listing. The issue price of the shares is  HKD 30.6 per share, and the amount of funds raised is HKD 2,085.89 million.
<img src="../../../../../uploads/Slide1_0a51fbaa7c.JPG" alt="" width="960" height="720" />

Congratulations to JST Group Corporation Limited (6687.HK) on its Successful Listing

Congratulations to Fujian Haixi Pharmaceutical Co., Ltd. (2637.HK) on its successful Listing on the Mainboard of HKSE on 20 Oct 2025
Fujian Haixi Pharmaceutical Co., Ltd. (“Haixi Pharmaceutical”) is a commercial-stage pharmaceutical company that integrates R&amp;D, production and sales capacities, with a pipeline of innovative drug candidates. Haixi Pharmaceutical has a diversified product portfolio and pipeline in the largest and fastest growing therapeutic areas in China. Haixi Pharmaceutical’s commercialized product portfolio primarily consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases.
With regard to this listing application, AVISTA Group is honored to be engaged in providing ESG advisory services, valuation services in relation to the financial asset and investment property.
Congratulations again Fujian Haixi Pharmaceutical Co., Ltd. (2637.HK) on its successful listing. The issue price of the shares is HKD86.4 per share, and the amount of funds raised is 993.6 million HKD.
<img src="../../../../../uploads/Slide1_79059e180b.JPG" alt="" width="960" height="720" />

News